Testing a new cream for itch relief in atopic dermatitis
Part of Genetic & congenital, Immune system & allergy, Skin clinical trials.
This study tests whether roflumilast cream (a new anti-inflammatory medication applied to the skin) can reduce the intense itching caused by atopic dermatitis (eczema). You'll track your itching daily using a smartphone app and visit the clinic to see if the cream helps over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 12 or older with a confirmed diagnosis of mild-to-moderate atopic dermatitis (eczema)
- Had eczema-related itching for at least 3 months and stable symptoms for the past 4 weeks (no major flares)
- Eczema affects at least 3% of your body (excluding scalp, palms, and soles)
- Moderate-to-severe itching score of 4 or higher on a standard pain scale
- Able to download and use a smartphone app to log itching once daily at the same time
- Not allergic to roflumilast or its ingredients; not pregnant or planning to become pregnant during the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a study drug (PF-08049820) for people with moderate to severe eczema who haven't found a suitable prescription treatment. It aims to see if the drug can improve skin symptoms and itching.
This trial tests if an ointment called QLM3003 is safe and helps adults with mild to moderate atopic dermatitis (eczema). It may be a new treatment option for people whose eczema affects small areas of skin.
This study tests a new medication called IBI3033 for people with moderate-to-severe atopic dermatitis (eczema) that hasn't improved with skin creams alone. The goal is to see if this drug can safely reduce itching, inflammation, and affected skin area.
This trial tests whether a cosmetic cream can reduce eczema flare-ups and is comfortable/safe to use on very dry, irritated, eczema-prone skin. It’s mainly for children who have had recent flare-ups and moderate eczema severity.
This study tests an oral medicine called roflumilast to see if it helps treat moderate to severe eczema in people aged 12 and up who haven't used other systemic treatments recently. It's a pilot study to check both safety and how well it works.
This study tests a new medication called IBI3002 for people with moderate to severe eczema (atopic dermatitis) that hasn't been well controlled by standard creams. The goal is to see if IBI3002 can reduce skin inflammation and itching.
Hear when a new Itch trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.